Wikipedia -WSS

Wikipedia

author：comprehensive 2025-08-12 06:43:27 - browse：1733

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Biotech execs pursue obesity drug boom: ‘It’s the early innings’

WSS

Listen: Biogen's potential pivot, & Illumina's next chapter

NIH nominee Bertagnolli will get October confirmation hearing

Inequities make cancer less preventable for women: report

Intercept Pharmaceuticals sells itself for less than $1 billion

A rare thyroid diagnosis led to unexpected, all

ALS advocates say criticism of new drugs misses bigger picture

knowledge

Wikipedia

entertainment

Affirmative action in medical school literally saved lives

Inequities make cancer less preventable for women: report

Walensky prepares to leave CDC — and Congress — behind

Medicaid rebukes states for mistakenly disenrolling children

Moonlake's readout produced a cash windfall. Risks remain

Ionis has late

The cancer drug shortage isn’t new — and neither are the solutions

NIH nominee Bertagnolli will get October confirmation hearing

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The 10 drugs up first for Medicare price negotiation

hotspot

Sudafed saga points to U.S. issues with evaluating older drugs

FDA seeks to regulate lab

Health tech startups drop sharply from 2021 highs

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Menendez indictment could see pharma lose a key ally

FDA seeks to regulate lab

explore

leisure time

focus

hotspot